Compile Data Set for Download or QSAR
Report error Found 104 Enz. Inhib. hit(s) with all data for entry = 856
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294359(US9586950, 26 | Methyl 4-cyano-2-(((3R,6R)-1-(2-cy...)
Affinity DataKi:  0.260nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294352(US9586950, 19 | methyl 4-cyano-2-{[(3R,6R)-6- meth...)
Affinity DataKi:  0.260nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294339(US9586950, 7 | methyl 4-cyano-2-{[(3R,6R)-1-{[2- f...)
Affinity DataKi:  0.330nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294333(US9586950, 2)
Affinity DataKi:  0.370nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294357(US9586950, 24 | methyl 4-cyano-2-({(3R,6R)-1-[(2- ...)
Affinity DataKi:  0.420nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294338(US9586950, 6 | methyl 4-cyano-2-{[(3R,6R)-1-{[5- f...)
Affinity DataKi:  0.420nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294336(US9586950, 4 | methyl 4-cyano-2-{[(3R,6R)-1-{[3- f...)
Affinity DataKi:  0.440nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294340(US9586950, 8 | methyl 4-cyano-2-{[(3R,6R)-1-{[5- f...)
Affinity DataKi:  0.440nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294306(US9586950, 1)
Affinity DataKi:  0.460nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294356(US9586950, 23 | methyl 4-cyano-2-({(3R,6R)-1-[(5- ...)
Affinity DataKi:  0.470nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294351(US9586950, 18 | methyl 4-cyano-2-{[(3R,6R)-6- meth...)
Affinity DataKi:  0.480nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294345(US9586950, 13 | methyl 4-cyano-2-{[(3R,6R)-1-{[5- ...)
Affinity DataKi:  0.5nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294343(US9586950, 11 | methyl 4-cyano-2-{[(3R,6R)-1-{[3- ...)
Affinity DataKi:  0.5nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294348(US9586950, 16 | methyl 4-cyano-2-{[(3R,6R)-6- meth...)
Affinity DataKi:  0.520nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294342(US9586950, 10 | methyl 4-cyano-2-{[(3R,6R)-6- meth...)
Affinity DataKi:  0.530nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataKi:  0.540nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294349(US9586950, 17 | methyl 4-cyano-2-{[(3R,6R)-6- meth...)
Affinity DataKi:  0.580nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294337(US9586950, 5 | methyl 4-cyano-2-{[(3R,6R)-1-{[4- f...)
Affinity DataKi:  0.660nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294355(US9586950, 22 | methyl 4-cyano-2-({(3R,6R)-1-[(4- ...)
Affinity DataKi:  0.680nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataKi:  0.760nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294346(US9586950, 14 | methyl 4-cyano-2-{[(3R,6R)-1-{[2- ...)
Affinity DataKi:  0.990nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294341(US9586950, 9 | methyl 4-cyano-2-{[(3R,6R)-1-{[2- f...)
Affinity DataKi:  1.10nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294344(US9586950, 12 | methyl 4-cyano-2-{[(3R,6R)-1-{[4- ...)
Affinity DataKi:  1.20nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294354(US9586950, 21 | methyl 4-cyano-2-({(3R,6R)-1-[(3- ...)
Affinity DataKi:  1.20nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294334(US9586950, 3 | methyl 4-cyano-2-{[(3R,6R)-1-{[6- m...)
Affinity DataKi:  1.90nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294347(US9586950, 15 | methyl 4-cyano-2-{[(3R,6R)-1-{[4- ...)
Affinity DataKi:  2.20nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294342(US9586950, 10 | methyl 4-cyano-2-{[(3R,6R)-6- meth...)
Affinity DataIC50: 6.5nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataIC50: 7nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294346(US9586950, 14 | methyl 4-cyano-2-{[(3R,6R)-1-{[2- ...)
Affinity DataIC50: 14.5nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294336(US9586950, 4 | methyl 4-cyano-2-{[(3R,6R)-1-{[3- f...)
Affinity DataIC50: 15.7nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294343(US9586950, 11 | methyl 4-cyano-2-{[(3R,6R)-1-{[3- ...)
Affinity DataIC50: 16.2nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294345(US9586950, 13 | methyl 4-cyano-2-{[(3R,6R)-1-{[5- ...)
Affinity DataIC50: 16.8nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294352(US9586950, 19 | methyl 4-cyano-2-{[(3R,6R)-6- meth...)
Affinity DataIC50: 16.9nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294338(US9586950, 6 | methyl 4-cyano-2-{[(3R,6R)-1-{[5- f...)
Affinity DataIC50: 18.2nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294306(US9586950, 1)
Affinity DataIC50: 19nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294359(US9586950, 26 | Methyl 4-cyano-2-(((3R,6R)-1-(2-cy...)
Affinity DataIC50: 19.3nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294333(US9586950, 2)
Affinity DataIC50: 20.8nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294337(US9586950, 5 | methyl 4-cyano-2-{[(3R,6R)-1-{[4- f...)
Affinity DataIC50: 21.8nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294351(US9586950, 18 | methyl 4-cyano-2-{[(3R,6R)-6- meth...)
Affinity DataIC50: 22nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataIC50: 23.8nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294339(US9586950, 7 | methyl 4-cyano-2-{[(3R,6R)-1-{[2- f...)
Affinity DataIC50: 24nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294349(US9586950, 17 | methyl 4-cyano-2-{[(3R,6R)-6- meth...)
Affinity DataIC50: 24.3nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294340(US9586950, 8 | methyl 4-cyano-2-{[(3R,6R)-1-{[5- f...)
Affinity DataIC50: 24.9nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294351(US9586950, 18 | methyl 4-cyano-2-{[(3R,6R)-6- meth...)
Affinity DataKi:  25.8nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294348(US9586950, 16 | methyl 4-cyano-2-{[(3R,6R)-6- meth...)
Affinity DataIC50: 27.7nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294344(US9586950, 12 | methyl 4-cyano-2-{[(3R,6R)-1-{[4- ...)
Affinity DataIC50: 30.2nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294353(US9586950, 20 | Methyl 4-cyano-2-({(3R,6-methyl-1-...)
Affinity DataKi:  30.8nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294347(US9586950, 15 | methyl 4-cyano-2-{[(3R,6R)-1-{[4- ...)
Affinity DataIC50: 31.8nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294356(US9586950, 23 | methyl 4-cyano-2-({(3R,6R)-1-[(5- ...)
Affinity DataIC50: 32nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294357(US9586950, 24 | methyl 4-cyano-2-({(3R,6R)-1-[(2- ...)
Affinity DataIC50: 32.8nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2019
Entry Details
US Patent

Displayed 1 to 50 (of 104 total ) | Next | Last >>
Jump to: